Insider Transactions in Q2 2022 at Arcutis Biotherapeutics, Inc. (ARQT)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
341,971
-7.97%
|
$7,181,391
$21.31 P/Share
|
|
Jun 23
2022
|
Todd Franklin Watanabe Director |
SELL
Bona fide gift
|
Direct |
268,964
-41.26%
|
-
|
|
Jun 06
2022
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
1,000
-0.15%
|
$21,000
$21.06 P/Share
|
|
Jun 02
2022
|
Masaru Matsuda Officer |
SELL
Open market or private sale
|
Direct |
1,795
-9.88%
|
$34,105
$19.73 P/Share
|
|
Jun 01
2022
|
Joseph L Turner Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,312
+50.0%
|
-
|
|
Jun 01
2022
|
Keith R Leonard Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,312
+50.0%
|
-
|
|
Jun 01
2022
|
Patrick J Heron Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,312
+50.0%
|
-
|
|
Jun 01
2022
|
Sue Jean Lin Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,312
+48.32%
|
-
|
|
Jun 01
2022
|
Howard G. Welgus Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,312
+2.26%
|
-
|
|
Jun 01
2022
|
Halley E Gilbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,312
+50.0%
|
-
|
|
Jun 01
2022
|
Bhaskar Chaudhuri Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,312
+0.51%
|
-
|
|
Jun 01
2022
|
Terrie Curran Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,312
+50.0%
|
-
|
|
Jun 01
2022
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
2,500
-1.36%
|
$50,000
$20.62 P/Share
|
|
Jun 01
2022
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+1.34%
|
$2,500
$1.68 P/Share
|
|
May 27
2022
|
Masaru Matsuda Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,875
+21.15%
|
-
|
|
May 05
2022
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
1,000
-0.15%
|
$21,000
$21.76 P/Share
|
|
May 02
2022
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
2,500
-1.36%
|
$50,000
$20.44 P/Share
|
|
May 02
2022
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.68%
|
$2,500
$1.13 P/Share
|
|
Apr 21
2022
|
David W Osborne Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
2,197
-0.85%
|
$43,940
$20.42 P/Share
|
|
Apr 08
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
200,000
-10.51%
|
$4,000,000
$20.71 P/Share
|
|
Apr 07
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
344,996
-14.16%
|
$6,899,920
$20.66 P/Share
|
|
Apr 06
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
333,204
-11.39%
|
$6,664,080
$20.69 P/Share
|
|
Apr 05
2022
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
1,000
-0.15%
|
$21,000
$21.43 P/Share
|
|
Apr 01
2022
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
7,500
-3.96%
|
$150,000
$20.02 P/Share
|
|
Apr 01
2022
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+3.81%
|
$0
$0.58 P/Share
|